NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, reported that its Phase IIA clinical trial of NV-387 Oral Gummies for Ebola Bundibugyo virus disease in the Democratic Republic of Congo is advancing, with a Phase IIB study anticipated after the initial phase concludes. Enrollment began on September 23, 2026, and approximately 20 patients are expected to participate in Phase IIA, which is designed to evaluate dosing regimens based on disease severity. The primary endpoint is 28-day survival, and the initial phase will end once the final enrolled patient completes the observation period.
The announcement comes as the DRC grapples with an ongoing Ebola Bundibugyo outbreak that has produced more than 10,000 confirmed cases and approximately 4,900 deaths, according to the company. NanoViricides noted that no treatments or vaccines are currently approved specifically for Ebola Bundibugyo, and that NV-387 Oral Gummies is, to its knowledge, the only oral drug candidate in clinical evaluation for the disease. The company is also testing NV-387 Oral Gummies in a separate Phase II trial for mpox in the DRC.
The lack of approved therapies for Ebola Bundibugyo underscores the public health significance of the trial. An oral antiviral could be particularly valuable in outbreak settings where healthcare infrastructure is limited, as it may simplify administration compared with injectable treatments. For investors, the progress of the Phase IIA trial represents a key milestone for NanoViricides, which is developing NV-387 as a broad-spectrum antiviral with potential applications against RSV, COVID-19, influenza, and other viral infections. The company’s pipeline also includes NV-HHV-1 for shingles.
NanoViricides emphasizes that drug development is lengthy and capital-intensive, and there is no assurance that its candidates will demonstrate sufficient effectiveness and safety for human clinical development. Nevertheless, the advancement of the Ebola trial and the parallel mpox study positions the company in areas of significant unmet medical need. More details are available in the full press release at https://ibn.fm/JJ69W, and the company’s website is www.nanoviricides.com.
The news was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution, among other corporate communications solutions. The platform aims to help companies reach investors, journalists, and the public. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
